{
    "Trade/Device Name(s)": [
        "Audit\u00ae MicroControls\u2122 Linearity FD Tumor Markers II"
    ],
    "Submitter Information": "Aalto Scientific, Ltd.",
    "510(k) Number": "K163629",
    "Predicate Device Reference 510(k) Number(s)": [
        "K130762"
    ],
    "Regulatory Class": "Class I, Reserved",
    "Product Code(s)": [
        "JJY",
        "JJX"
    ],
    "Summary Letter Date": "December 21, 2016",
    "Summary Letter Received Date": "January 11, 2017",
    "Submission Date": "March 06, 2017",
    "Regulation Number(s)": [
        "21CFR862.1660"
    ],
    "Regulation Name(s)": [
        "Quality control material (assayed and unassayed)"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "cancer molecular"
    ],
    "Analyte(s)": [
        "HE4",
        "HER2"
    ],
    "Specimen Type(s)": [
        "Human Serum"
    ],
    "Specimen Container(s)": [
        ""
    ],
    "Instrument(s)/Platform(s)": [
        "Siemens Centaur XP",
        "Roche Cobas e411"
    ],
    "Method(s)/Technology(ies)": [
        "Immunoassay"
    ],
    "Methodologies": [
        "Calibration verification",
        "Linearity assessment"
    ],
    "Submission Type(s)": [
        "Quality control material",
        "Calibrator"
    ],
    "Document Summary": "FDA 510(k) summary for Audit MicroControls Linearity FD Tumor Markers II, a freeze-dried multi-analyte quality control for HE4 and HER2 in human serum.",
    "Indications for Use Summary": "Intended to simulate human patient samples for use as assayed quality control material in determining linearity, calibration verification, and reportable range for HE4 and HER2 analytes in vitro.",
    "fda_folder": "Clinical Chemistry"
}